Assessment of GVG for the Treatment of Methamphetamine Dependence

Methamphetamine Addiction Clinical Trial

Official title:
Phase 1 Study of Vigabatrin (GVG) for Methamphetamine Dependence

Status Completed

Clinical Trial Summary

The purpose of this study is to find out if GVG can reduce drug use and determine safety and effects of GVG when used together with methamphetamine. This study involves staying in the hospital for 21 days. Participants will receive either placebo or GVG, and a limited amount if methamphetamine will be injected on some study days. This study will enroll people that use methamphetamine. Participants will be compensated.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Methamphetamine Addiction

Clinical Trial Details

NCT number	NCT00506935
Study type	Interventional
Source	Baylor College of Medicine
Contact
Status	Completed
Phase	Phase 1
Start date	July 2006
Completion date	June 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00630682` - A Pilot Trial of Dextroamphetamine for Methamphetamine Dependence	Phase 2
Completed	`NCT00713479` - An Assessment of the Safety of Varenicline in Methamphetamine-dependent Volunteers	Phase 1
Completed	`NCT00538655` - A Pilot Trial of Modafinil for Treatment of Methamphetamine Dependence	Phase 2